Table 6.
Intention to Treat Analysis
|
|
PFS in months Median (95% CI) |
OS in months Median (95% CI) |
P-value | Hazard Ratio Cox Regression |
|||
|---|---|---|---|---|---|---|---|
| Log-rank | (95% CI) P-value |
||||||
| All patients (N-211) | 10 (9–12) | 23 (20–29) | PFS | OS | PFS | OS | |
| High TS | Arm A IROX/Bev |
9 |
20 | A vs B 0.55 |
A vs B 0.22 |
A vs B 1.1 (0.8–1.6) P=0.55 |
A vs B 1.3 (0.9–1.9) P=0.23 |
| Arm B FOLFOX/Bev |
9 |
21 | |||||
| TS Low | Arm C FOLFOX/Bev |
13 |
32 | B vs C 0.02 |
B vs C 0.04 |
B vs C 1.6 (1.1–2.4) 0.02 |
B vs C 1.3 (0.9–1.9) 0.23 |
TS = thymidylate synthase; IROX = irinotecan and oxaliplatin; Bev = bevacizumab; FOLFOX = folinic acid (leucovorin), 5-Fluorouracil, and oxaliplatin; CI = confidence interval; PFS = progression-free survival; OS = overall survival. The TS-Low cohort includes both TS-Low and TS-indeterminate expression